{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T07:46:00Z","timestamp":1794555960495,"version":"4.9.1"},"reference-count":47,"publisher":"American Medical Association (AMA)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Ophthalmol"],"published-print":{"date-parts":[[2024,4,1]]},"abstract":"<jats:sec id=\"ab-eoi240007-4\">\n                    <jats:title>Importance<\/jats:title>\n                    <jats:p>Existing therapies to slow geographic atrophy (GA) enlargement in age-related macular degeneration (AMD) have relatively modest anatomic efficacy, require intravitreal administration, and increase the risk of neovascular AMD. Additional therapeutic approaches are desirable.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-eoi240007-5\">\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To evaluate the safety and possible anatomic efficacy of oral minocycline, a microglial inhibitor, for the treatment of GA in AMD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-eoi240007-6\">\n                    <jats:title>Design, Setting, and Participants<\/jats:title>\n                    <jats:p>This was a phase 2, prospective, single-arm, 45-month, nonrandomized controlled trial conducted from December 2016 to April 2023. Patients with GA from AMD in 1 or both eyes were recruited from the  National Institutes of Health (Bethesda, Maryland) and Bristol Eye Hospital (Bristol, UK). Study data were analyzed from September 2022 to May 2023.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-eoi240007-7\">\n                    <jats:title>Intervention<\/jats:title>\n                    <jats:p>After a 9-month run-in phase, participants began oral minocycline, 100 mg, twice daily for 3 years.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-eoi240007-8\">\n                    <jats:title>Main Outcomes and Measures<\/jats:title>\n                    <jats:p>The primary outcome measure was the difference in rate of change of square root GA area on fundus autofluorescence between the 24-month treatment phase and 9-month run-in phase.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-eoi240007-9\">\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Of the 37 participants enrolled (mean [SD] age, 74.3 [7.6] years; 21 female [57%]), 36 initiated the treatment phase. Of these participants, 21 (58%) completed at least 33 months, whereas 15 discontinued treatment (8 by request, 6 for adverse events\/illness, and 1 death). Mean (SE) square root GA enlargement rate in study eyes was 0.31 (0.03) mm per year during the run-in phase and 0.28 (0.02) mm per year during the treatment phase. The primary outcome measure of mean (SE) difference in enlargement rates between the 2 phases was \u22120.03 (0.03) mm per year (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u2009.39). Similarly, secondary outcome measures of GA enlargement rate showed no differences between the 2 phases. The secondary outcome measures of mean difference in rate of change between 2 phases were 0.2 letter score per month (95% CI, \u22120.4 to 0.9;\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u2009.44) for visual acuity and 0.7 \u03bcm per month (\u22120.4 to 1.8;\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u2009.20) for subfoveal retinal thickness. Of the 129 treatment-emergent adverse events among 32 participants, 49 (38%) were related to minocycline (with no severe or ocular events), including elevated thyrotropin level (15 participants) and skin hyperpigmentation\/discoloration (8 participants).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-eoi240007-10\">\n                    <jats:title>Conclusions and Relevance<\/jats:title>\n                    <jats:p>In this phase 2 nonrandomized controlled trial, oral minocycline was not associated with a decrease in GA enlargement over 24 months, compared with the run-in phase. This observation was consistent across primary and secondary outcome measures. Oral minocycline at this dose is likely not associated with slower rate of enlargement of GA in AMD.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1001\/jamaophthalmol.2024.0118","type":"journal-article","created":{"date-parts":[[2024,3,14]],"date-time":"2024-03-14T11:01:17Z","timestamp":1710414077000},"page":"345","source":"Crossref","is-referenced-by-count":17,"title":["Phase 2 Trial Evaluating Minocycline for Geographic Atrophy in Age-Related Macular Degeneration"],"prefix":"10.1001","volume":"142","author":[{"given":"Tiarnan D. L.","family":"Keenan","sequence":"first","affiliation":[{"name":"National Eye Institute, National Institutes of Health, Bethesda, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clare","family":"Bailey","sequence":"additional","affiliation":[{"name":"Bristol Eye Hospital, Bristol, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Abraham","sequence":"additional","affiliation":[{"name":"The Emmes Company LLC, Rockville, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Orndahl","sequence":"additional","affiliation":[{"name":"The Emmes Company LLC, Rockville, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Supriya","family":"Menezes","sequence":"additional","affiliation":[{"name":"The Emmes Company LLC, Rockville, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sunil","family":"Bellur","sequence":"additional","affiliation":[{"name":"National Eye Institute, National Institutes of Health, Bethesda, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thilaka","family":"Arunachalam","sequence":"additional","affiliation":[{"name":"National Eye Institute, National Institutes of Health, Bethesda, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cathy","family":"Kangale-Whitney","sequence":"additional","affiliation":[{"name":"National Eye Institute, National Institutes of Health, Bethesda, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sowmya","family":"Srinivas","sequence":"additional","affiliation":[{"name":"Doheny Eye Institute, Pasadena, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayesha","family":"Karamat","sequence":"additional","affiliation":[{"name":"Doheny Eye Institute, Pasadena, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muneeswar","family":"Nittala","sequence":"additional","affiliation":[{"name":"Doheny Eye Institute, Pasadena, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denise","family":"Cunningham","sequence":"additional","affiliation":[{"name":"National Eye Institute, National Institutes of Health, Bethesda, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brett G.","family":"Jeffrey","sequence":"additional","affiliation":[{"name":"National Eye Institute, National Institutes of Health, Bethesda, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henry E.","family":"Wiley","sequence":"additional","affiliation":[{"name":"National Eye Institute, National Institutes of Health, Bethesda, Maryland"},{"name":"Now with Genentech Inc, South San Francisco, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alisa T.","family":"Thavikulwat","sequence":"additional","affiliation":[{"name":"National Eye Institute, National Institutes of Health, Bethesda, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"SriniVas","family":"Sadda","sequence":"additional","affiliation":[{"name":"Doheny Eye Institute, Pasadena, California"},{"name":"University of California, Los Angeles, Los Angeles"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine A.","family":"Cukras","sequence":"additional","affiliation":[{"name":"National Eye Institute, National Institutes of Health, Bethesda, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily Y.","family":"Chew","sequence":"additional","affiliation":[{"name":"National Eye Institute, National Institutes of Health, Bethesda, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wai T.","family":"Wong","sequence":"additional","affiliation":[{"name":"National Eye Institute, National Institutes of Health, Bethesda, Maryland"},{"name":"Now with Janssen Research and Development LLC, Brisbane, California"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"9","key":"eoi240007r1","doi-asserted-by":"publisher","first-page":"3456","DOI":"10.1167\/iovs.17-22339","article-title":"Report from the NEI\/FDA Endpoints Workshop on age-related macular degeneration and inherited retinal diseases.","volume":"58","author":"Csaky","year":"2017","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"2","key":"eoi240007r4","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1016\/j.ophtha.2019.07.011","article-title":"Complement C3 inhibitor pegcetacoplan for geographic atrophy secondary to age-related macular degeneration: a randomized phase 2 trial.","volume":"127","author":"Liao","year":"2020","journal-title":"Ophthalmology"},{"issue":"4","key":"eoi240007r5","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1016\/j.ophtha.2020.08.027","article-title":"C5 inhibitor avacincaptad pegol for geographic atrophy due to age-related macular degeneration: a randomized pivotal phase 2\/3 trial.","volume":"128","author":"Jaffe","year":"2021","journal-title":"Ophthalmology"},{"issue":"1","key":"eoi240007r6","doi-asserted-by":"publisher","first-page":"7028","DOI":"10.1038\/s41598-023-34139-2","article-title":"Clinical validation for automated geographic atrophy monitoring on OCT under complement inhibitory treatment.","volume":"13","author":"Mai","year":"2023","journal-title":"Sci Rep"},{"issue":"1","key":"eoi240007r7","doi-asserted-by":"publisher","first-page":"17870","DOI":"10.1038\/s41598-022-22404-9","article-title":"Association of complement C3 inhibitor pegcetacoplan with reduced photoreceptor degeneration beyond areas of geographic atrophy.","volume":"12","author":"Pfau","year":"2022","journal-title":"Sci Rep"},{"key":"eoi240007r8","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1007\/978-3-030-66014-7","article-title":"Innate immunity in age-related macular degeneration.","volume":"1256","author":"Zhang","year":"2021","journal-title":"Adv Exp Med Biol"},{"key":"eoi240007r9","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1007\/978-3-030-66014-7","article-title":"Immunological aspects of age-related macular degeneration.","volume":"1256","author":"Allingham","year":"2021","journal-title":"Adv Exp Med Biol"},{"issue":"1","key":"eoi240007r10","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1038\/s41572-021-00265-2","article-title":"Age-related macular degeneration.","volume":"7","author":"Fleckenstein","year":"2021","journal-title":"Nat Rev Dis Primers"},{"key":"eoi240007r11","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.preteyeres.2017.06.002","article-title":"On phagocytes and macular degeneration.","volume":"61","author":"Guillonneau","year":"2017","journal-title":"Prog Retin Eye Res"},{"issue":"2","key":"eoi240007r12","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1111\/opo.v40.2","article-title":"Contribution of microglia and monocytes to the development and progression of age-related macular degeneration.","volume":"40","author":"Fletcher","year":"2020","journal-title":"Ophthalmic Physiol Opt"},{"issue":"2","key":"eoi240007r13","doi-asserted-by":"publisher","first-page":"211","DOI":"10.15252\/emmm.201404524","article-title":"Apolipoprotein E promotes subretinal mononuclear phagocyte survival and chronic inflammation in age-related macular degeneration.","volume":"7","author":"Levy","year":"2015","journal-title":"EMBO Mol Med"},{"key":"eoi240007r14","doi-asserted-by":"publisher","DOI":"10.1016\/j.exer.2022.109170","article-title":"Cell culture models to study retinal pigment epithelium-related pathogenesis in age-related macular degeneration.","volume":"222","author":"Bharti","year":"2022","journal-title":"Exp Eye Res"},{"issue":"1","key":"eoi240007r15","doi-asserted-by":"publisher","first-page":"3347","DOI":"10.1038\/s41467-019-11262-1","article-title":"A systems biology approach towards understanding and treating nonneovascular age-related macular degeneration.","volume":"10","author":"Handa","year":"2019","journal-title":"Nat Commun"},{"key":"eoi240007r16","doi-asserted-by":"publisher","DOI":"10.1016\/j.exer.2020.108404","article-title":"Progress in developing rodent models of age-related macular degeneration (AMD).","volume":"203","author":"Soundara Pandi","year":"2021","journal-title":"Exp Eye Res"},{"key":"eoi240007r17","doi-asserted-by":"publisher","DOI":"10.1016\/j.preteyeres.2020.100880","article-title":"Retina in a dish: Cell cultures, retinal explants, and animal models for common diseases of the retina.","volume":"81","author":"Schnichels","year":"2021","journal-title":"Prog Retin Eye Res"},{"issue":"26","key":"eoi240007r18","doi-asserted-by":"publisher","first-page":"15769","DOI":"10.1073\/pnas.95.26.15769","article-title":"Tetracyclines inhibit microglial activation and are neuroprotective in global brain ischemia.","volume":"95","author":"Yrj\u00e4nheikki","year":"1998","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"23","key":"eoi240007r19","doi-asserted-by":"publisher","first-page":"13496","DOI":"10.1073\/pnas.96.23.13496","article-title":"A tetracycline derivative, minocycline, reduces inflammation and protects against focal cerebral ischemia with a wide therapeutic window.","volume":"96","author":"Yrj\u00e4nheikki","year":"1999","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"3","key":"eoi240007r20","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1111\/jnc.2005.94.issue-3","article-title":"Antioxidant properties of minocycline: neuroprotection in an oxidative stress assay and direct radical-scavenging activity.","volume":"94","author":"Kraus","year":"2005","journal-title":"J Neurochem"},{"issue":"5","key":"eoi240007r21","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1111\/jnc.2004.91.issue-5","article-title":"Minocycline prevents glutamate-induced apoptosis of cerebellar granule neurons by differential regulation of p38 and Akt pathways.","volume":"91","author":"Pi","year":"2004","journal-title":"J Neurochem"},{"issue":"1-2","key":"eoi240007r22","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/j.brainres.2005.06.053","article-title":"Neuroprotective effects of minocycline against in vitro and in vivo retinal ganglion cell damage.","volume":"1053","author":"Shimazawa","year":"2005","journal-title":"Brain Res"},{"issue":"5","key":"eoi240007r23","doi-asserted-by":"publisher","first-page":"1559","DOI":"10.2337\/diabetes.54.5.1559","article-title":"Minocycline reduces proinflammatory cytokine expression, microglial activation, and caspase-3 activation in a rodent model of diabetic retinopathy.","volume":"54","author":"Krady","year":"2005","journal-title":"Diabetes"},{"issue":"3","key":"eoi240007r24","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1016\/j.ajpath.2011.05.042","article-title":"Minocycline attenuates photoreceptor degeneration in a mouse model of subretinal hemorrhage microglial: inhibition as a potential therapeutic strategy.","volume":"179","author":"Zhao","year":"2011","journal-title":"Am J Pathol"},{"issue":"6","key":"eoi240007r25","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.1016\/j.exer.2004.02.002","article-title":"Minocycline delays photoreceptor death in the rds mouse through a microglia-independent mechanism.","volume":"78","author":"Hughes","year":"2004","journal-title":"Exp Eye Res"},{"key":"eoi240007r26","first-page":"1073","article-title":"Minocycline delayed photoreceptor death in rds mice through iNOS-dependent mechanism.","volume":"13","author":"Yang","year":"2007","journal-title":"Mol Vis"},{"issue":"2","key":"eoi240007r27","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1111\/bph.2013.169.issue-2","article-title":"Minocycline: far beyond an antibiotic.","volume":"169","author":"Garrido-Mesa","year":"2013","journal-title":"Br J Pharmacol"},{"issue":"8","key":"eoi240007r28","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1016\/j.ophtha.2020.02.009","article-title":"A deep-learning model for segmentation of geographic atrophy to study its long-term natural history.","volume":"127","author":"Liefers","year":"2020","journal-title":"Ophthalmology"},{"issue":"9","key":"eoi240007r29","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1016\/j.oret.2018.01.019","article-title":"Natural history of geographic atrophy in untreated eyes with nonexudative age-related macular degeneration: a systematic review and meta-analysis.","volume":"2","author":"Shen","year":"2018","journal-title":"Ophthalmol Retina"},{"issue":"4","key":"eoi240007r30","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1016\/j.ophtha.2010.08.018","article-title":"Progression of geographic atrophy in age-related macular degeneration imaged with spectral domain optical coherence tomography.","volume":"118","author":"Yehoshua","year":"2011","journal-title":"Ophthalmology"},{"issue":"1","key":"eoi240007r31","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1001\/jamaophthalmol.2013.572","article-title":"Square root transformation of geographic atrophy area measurements to eliminate dependence of growth rates on baseline lesion measurements: a reanalysis of age-related eye disease study report No. 26.","volume":"131","author":"Feuer","year":"2013","journal-title":"JAMA Ophthalmol"},{"issue":"4","key":"eoi240007r32","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1046\/j.1365-2710.2002.00430.x","article-title":"Segmented regression analysis of interrupted time series studies in medication use research.","volume":"27","author":"Wagner","year":"2002","journal-title":"J Clin Pharm Ther"},{"issue":"13","key":"eoi240007r34","doi-asserted-by":"publisher","first-page":"8020","DOI":"10.1167\/iovs.13-12302","article-title":"Optical coherence tomographic correlates of angiographic subtypes of occult choroidal neovascularization.","volume":"54","author":"Hariri","year":"2013","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"13","key":"eoi240007r35","doi-asserted-by":"publisher","first-page":"8375","DOI":"10.1167\/iovs.13-12552","article-title":"Segmentation of the geographic atrophy in spectral-domain optical coherence tomography and fundus autofluorescence images.","volume":"54","author":"Hu","year":"2013","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"4","key":"eoi240007r37","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.23754","article-title":"Doxycycline-associated hyperpigmentation: a case report and literature review.","volume":"14","author":"Afrin","year":"2022","journal-title":"Cureus"},{"issue":"7","key":"eoi240007r38","doi-asserted-by":"publisher","first-page":"3755","DOI":"10.3390\/ijms22073755","article-title":"Molecular and biochemical basis of minocycline-induced hyperpigmentation\u2014the study on normal human melanocytes exposed to UVA and UVB radiation.","volume":"22","author":"Rok","year":"2021","journal-title":"Int J Mol Sci"},{"issue":"4","key":"eoi240007r39","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1016\/j.jaad.2022.10.007","article-title":"Differences in risk of tetracycline-associated hyperpigmentation between racial and ethnic groups in patients with acne vulgaris: a national US retrospective study.","volume":"88","author":"Young","year":"2023","journal-title":"J Am Acad Dermatol"},{"issue":"7-8","key":"eoi240007r40","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1080\/14764172.2017.1418514","article-title":"Picosecond alexandrite laser is superior to Q-switched Nd:YAG laser in treatment of minocycline-induced hyperpigmentation: a case study and review of the literature.","volume":"20","author":"Barrett","year":"2018","journal-title":"J Cosmet Laser Ther"},{"issue":"1","key":"eoi240007r42","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/s13044-023-00149-5","article-title":"Age-related variation in thyroid function\u2014a narrative review highlighting important implications for research and clinical practice.","volume":"16","author":"Taylor","year":"2023","journal-title":"Thyroid Res"},{"issue":"2","key":"eoi240007r44","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/j.ophtha.2006.09.016","article-title":"The long-term natural history of geographic atrophy from age-related macular degeneration: enlargement of atrophy and implications for interventional clinical trials.","volume":"114","author":"Sunness","year":"2007","journal-title":"Ophthalmology"},{"issue":"6","key":"eoi240007r46","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1001\/jamaophthalmol.2018.1544","article-title":"Efficacy and safety of lampalizumab for geographic atrophy due to age-related macular degeneration: Chroma and Spectri Phase 3 randomized clinical trials.","volume":"136","author":"Holz","year":"2018","journal-title":"JAMA Ophthalmol"},{"issue":"12","key":"eoi240007r47","doi-asserted-by":"publisher","first-page":"1913","DOI":"10.1016\/j.ophtha.2018.05.028","article-title":"Progression of geographic atrophy in age-related macular degeneration: AREDS2 report number 16.","volume":"125","author":"Keenan","year":"2018","journal-title":"Ophthalmology"},{"key":"eoi240007r33","doi-asserted-by":"crossref","DOI":"10.1002\/9781119513469","volume-title":"Applied Longitudinal Analysis","author":"Fitzmaurice","year":"2011"},{"key":"eoi240007r43","volume-title":"Endotext [Internet]","author":"Kim","year":"2000"},{"key":"eoi240007r2","unstructured":"Apellis Pharmaceuticals. FDA approves SYFOVRE (pegcetacoplan injection) as the first and only treatment for geographic atrophy (GA), a leading cause of blindness. Accessed February 28, 2023. https:\/\/investors.apellis.com\/news-releases\/news-release-details\/fda-approves-syfovretm-pegcetacoplan-injection-first-and-only"},{"key":"eoi240007r3","unstructured":"Iveric Bio. Iveric Bio receives US FDA approval for IZERVAY (avacincaptad pegol intravitreal solution), a new treatment for geographic atrophy. Accessed August 11, 2023. https:\/\/ivericbio.com\/iveric-bio-receives-us-fda-approval-for-izervay-avacincaptad-pegol-intravitreal-solution-a-new-treatment-for-geographic-atrophy\/"},{"key":"eoi240007r36","unstructured":"Evaluation of Oral Minocycline in the Treatment of Geographic Atrophy Associated With Age-Related Macular Degeneration. ClinicalTrials.gov identifier: NCT02564978. Updated September 23, 2022. Accessed July 7, 2023. https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT02564978"},{"key":"eoi240007r41","unstructured":"US Food and Drug Administration. Minocin (minocycline hydrochloride) pellet-filled capsules. Accessed June 12, 2023. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2010\/050649023lbl.pdf"},{"key":"eoi240007r45","unstructured":"Clinical Study to Evaluate Treatment With ORACEA for Geographic Atrophy (TOGA). ClinicalTrials.gov identifier: NCT01782989. Updated November 4, 2022. Accessed December 12, 2022. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01782989"}],"container-title":["JAMA Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamaophthalmology\/articlepdf\/2816207\/jamaophthalmology_keenan_2024_oi_240007_1712159398.21722.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,18]],"date-time":"2024-04-18T11:02:17Z","timestamp":1713438137000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamaophthalmology\/fullarticle\/2816207"}},"subtitle":["A Nonrandomized Controlled Trial"],"short-title":[],"issued":{"date-parts":[[2024,4,1]]},"references-count":47,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,4,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamaophthalmol.2024.0118","relation":{},"ISSN":["2168-6165"],"issn-type":[{"value":"2168-6165","type":"print"}],"subject":[],"published":{"date-parts":[[2024,4,1]]}}}